Arch Therapeutics Inc (ARTH)

[Regis999]

Arch Therapeutics ARTH Drill Down

There is substantially less risk in ARTH today than last week with human trials in.

Arch has only 4 employees so impossible to communicate.

Therefore we ALL need to request public conference calls on events like today. Please encourage them to have a public conference all asap. This is important and the time has come for Dr. Norchi to shine on this type of venue.

I was told all the physicians involved in the human clinical thought the 41% faster on skin lesions was a Huge Deal as they do not bleed a lot--2 to 3 minutes.

This was an easy first step AC5 bleeding challenge. The market assumed same. A major arterial bleeding event using AC5 will bring in the major investors.



As far as the CE Mark they are applying for a "top line" CE Mark which requires a little more time.


What I want to know is how many of the 200 +- AC5 applications will this human trial permit? So the big dollar low hanging fruit (my term) is external applications: Pressure Ulcers (bedsores)--2.5 million cases in USA costing $ 10 BILLION, Foot ulcers, Burns, Colon Surgery leakage issues, etc. IMHO the external $ uses dwarf the surgery apps. What are the 200 applications????